High income (World Bank) vs Saudi Arabia: Measles-containing-vaccine second-dose (MCV2) immunization coverage
High income (World Bank)
91.0%
in 2025
Saudi Arabia
99.0%
in 2025
High income (World Bank) rank
2nd
Saudi Arabia rank
1st
Measles-containing-vaccine second-dose (MCV2) immunization coverage over time
- High income (World Bank)
- Saudi Arabia
How they compare
Saudi Arabia currently reports 99.0% against 91.0% in High income (World Bank), a difference of 8.0%.
That makes Saudi Arabia's figure about 1.1 times High income (World Bank)'s.
The two have swapped places 1 time across 26 shared years of data; in 2000 it was High income (World Bank) ahead.
High income (World Bank) ranks 2nd and Saudi Arabia ranks 1st of 11 groups.
Saudi Arabia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | High income (World Bank) | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 65.6% | 87.4% | 21.8% | Saudi Arabia |
| 2010s | 89.4% | 97.1% | 7.7% | Saudi Arabia |
| 2020s | 91.5% | 97.0% | 5.5% | Saudi Arabia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher measles-containing-vaccine second-dose (mcv2) immunization coverage, High income (World Bank) or Saudi Arabia?
- Saudi Arabia, at 99.0% against 91.0% in High income (World Bank) as of 2025.
- What is the difference in measles-containing-vaccine second-dose (mcv2) immunization coverage between High income (World Bank) and Saudi Arabia?
- 8.0%, with Saudi Arabia ahead.
- How many years of comparable data are there for High income (World Bank) and Saudi Arabia?
- 26 years are reported by both, from 2000 to 2025.
- How do High income (World Bank) and Saudi Arabia rank globally for measles-containing-vaccine second-dose (mcv2) immunization coverage?
- High income (World Bank) ranks 2nd and Saudi Arabia ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Measles-containing-vaccine second-dose (MCV2) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.